TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25481712

Group type: EXPERIMENTAL
Intervention: KRAS mutations in pancreatic juice from patients with pancreatic cancer (n = 30)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: KRAS mutations in pancreatic juice from asymptomatic individuals at high risk for pancreatic cancer
Number of subjects: 272

Group type: COMPARATOR
Intervention: KRAS mutations in pancreatic juice from controls (n = 48)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: KRAS mutations detected 3 or more times in patients with pancreatic cancer
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: KRAS mutations detected 3 or more times in screened subjects
Number of subjects: 272

Group type: COMPARATOR
Intervention: KRAS mutations detected 3 or more times in controls
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: KRAS mutations in patients older than age 50 years
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: KRAS mutations in younger patients
Number of subjects: 272
Study: 25481820

Group type: EXPERIMENTAL
Intervention: Glucagon stimulation test (GST) with 1mg of glucagon via intramuscular injection
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Glucagon stimulation test (GST)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No side effects during GST
Number of subjects: 42
Study: 25482239

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 23
Study: 25482244

Group type: EXPERIMENTAL
Intervention: Orthostat-L™ (hemostatic putty loaded with lidocaine)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Orthostat™ (hemostatic putty without lidocaine)
Number of subjects: 14
Study: 25483909

Group type: EXPERIMENTAL
Intervention: peginterferon α plus ribavirin
Number of subjects: 1128

Group type: EXPERIMENTAL
Intervention: Treatment discontinuation reasons
Number of subjects: 1128

Group type: EXPERIMENTAL
Intervention: Lost to follow-up
Number of subjects: 1128
Study: 25485670

Group type: EXPERIMENTAL
Intervention: Eating six to seven family meals/week while growing up
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Eating frequent family meals while growing up
Number of subjects: 160
Study: 25486127

Group type: EXPERIMENTAL
Intervention: bortezomib+melphalan+prednisone (VMP)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: bortezomib±dexamethasone (V±D)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: melphalan+prednisone+thalidomide (MPT)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: lenalidomide+dexamethasone (LD)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: bortezomib-based regimens
Number of subjects: 371

Group type: COMPARATOR
Intervention: bortezomib retherapy
Number of subjects: 371
Study: 25486412

Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy (5-fluorouracil with interferon-α and gemcitabine with oxaliplatin)
Number of subjects: 0
Study: 25486575

Group type: EXPERIMENTAL
Intervention: Stem cell-based therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current therapeutic approaches
Number of subjects: 0
Study: 25487791

Group type: EXPERIMENTAL
Intervention: Ceftaroline
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 1116
Study: 25487797

Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 20
Study: 25488930

Group type: EXPERIMENTAL
Intervention: 140 mg of ¹⁴C-labeled ibrutinib
Number of subjects: 0
Study: 25488966

Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg IV once per week and Bevacizumab 10 mg/kg IV once every 2 weeks
Number of subjects: 58
Study: 25489010

Group type: EXPERIMENTAL
Intervention: Review of clinical care in NICUs
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Extreme prematurity and complications of premature birth
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Hypoxic-ischemic encephalopathy and genetic or structural anomalies
Number of subjects: 641
Study: 25490898

Group type: EXPERIMENTAL
Intervention: Spanish Black Radish supplementation for 4 weeks
Number of subjects: 0
Study: 25491305

Group type: EXPERIMENTAL
Intervention: Minocycline (3 mg/kg/day for 8 weeks)
Number of subjects: 25
Study: 25491381

Group type: EXPERIMENTAL
Intervention: miniDOX regimen (D: 40 mg/m(2) iv, day 1; O: 80 mg/m(2) iv, day 1; C: 625 mg/m(2) po bid, day 1 to day 21, every 21 days; after six courses, only C was maintained)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: miniDOX regimen
Number of subjects: 43
Study: 25491944

Group type: EXPERIMENTAL
Intervention: Endotracheal tubes (ETTs) with varying inner diameters (2.0-4.5 mm) from four manufacturers
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Shortened ETTs (25% reduction in length)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Comparison of Ptrach to Paw
Number of subjects: 9
Study: 25492104

Group type: EXPERIMENTAL
Intervention: GTX (gemcitabine, docetaxel, and capecitabine)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: GX/RT (gemcitabine and capecitabine/radiation therapy)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: GTX plus GX/RT
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: GX/RT
Number of subjects: 45
Study: 25492452

Group type: EXPERIMENTAL
Intervention: POEM (peroral endoscopic myotomy)
Number of subjects: 32
Study: 25492835

Group type: EXPERIMENTAL
Intervention: Nebivolol and Valsartan (5/160 mg/d initially, titrated to 20/320 mg/d)
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Nebivolol and Valsartan
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Nebivolol and Valsartan with Hydrochlorothiazide
Number of subjects: 810
Study: 25492908

Group type: EXPERIMENTAL
Intervention: Follow-up imaging after recanalization
Number of subjects: 126
Study: 25492923

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (100 mg/m(2) weekly for 3 weeks followed by a 1-week break)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Number of subjects: 40
Study: 25492955

Group type: EXPERIMENTAL
Intervention: Group B (COPD GOLD group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Group D (COPD GOLD group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Group A (COPD GOLD group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: All groups (COPD GOLD groups A-D)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: COPD combined classification
Number of subjects: 44
Study: 25493362

Group type: EXPERIMENTAL
Intervention: ALPPS (Associating liver partition and portal vein ligation for staged hepatectomy)
Number of subjects: 30
Study: 25493435

Group type: EXPERIMENTAL
Intervention: Agitated patients (n=35)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia and balanced anesthesia with short duration
Number of subjects: 123
Study: 25494494

Group type: EXPERIMENTAL
Intervention: Knowledge-driven method to represent electrodermal activity (EDA) using EDA-specific dictionaries and greedy sparse representation techniques.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous studies fitting a predetermined structure to the signal.
Number of subjects: 0
Study: 25494662

Group type: EXPERIMENTAL
Intervention: Chronocort (10 mg at 0700 h and 20 mg at 2300 h)
Number of subjects: 16
Study: 25495067

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (4-8 weeks) consisting of basal detemir and pre-meal insulin aspart
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 97
Study: 25495896

Group type: EXPERIMENTAL
Intervention: Ropinirole XL/PR (maximum 24 mg/d)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Ropinirole XL/PR (once-daily dosing)
Number of subjects: 419
Study: 25496316

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat(®) (1.25-10 μg) or HandiHaler(®) (18 μg) once daily for periods of up to 48 weeks
Number of subjects: 727

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 727
Study: 25496614

Group type: EXPERIMENTAL
Intervention: HPV-DNA detection
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: HPV prevalence by age group
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: HPV type distribution
Number of subjects: 417

Group type: COMPARATOR
Intervention: HPV prevalence comparison
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Awareness of HPV
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Interest in HPV vaccination
Number of subjects: 417
Study: 25497320

Group type: EXPERIMENTAL
Intervention: WOMAC pain, function, stiffness, and total scores
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: VAS pain score
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Meniscal extrusion in medial and lateral compartments
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Meniscal tears in lateral compartment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bone marrow lesions in lateral plateau
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Extent of synovial membrane thickness in lateral recess
Number of subjects: 50
Study: 25497517

Group type: EXPERIMENTAL
Intervention: Task-specific training (inpatient sample)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Task-specific training (outpatient sample)
Number of subjects: 35
Study: 25497535

Group type: EXPERIMENTAL
Intervention: Elevated cTnT serum level
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: cTnT serum levels
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Creatinine, NT-proBNP, male gender
Number of subjects: 200
Study: 25497558

Group type: EXPERIMENTAL
Intervention: Endostar (7.5mg/m(2)/d) for 7 days at weeks 1, 3, 5, and 7, with concurrent chemoradiotherapy (CCRT) including docetaxel (65mg/m(2)) and cisplatin (65mg/m(2)) on days 8 and 36, and thoracic radiation to a dose of 60-66Gy.
Number of subjects: 50
Study: 25497691

Group type: EXPERIMENTAL
Intervention: High-dose testosterone treatment in female-to-male transsexuals
Number of subjects: 33

Group type: COMPARATOR
Intervention: Antiandrogen and estrogen treatment in male-to-female transsexuals
Number of subjects: 33
Study: 25498193

Group type: EXPERIMENTAL
Intervention: FUSION vascular graft (6-mm, 7-mm, or 8-mm)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: FUSION vascular graft
Number of subjects: 117
Study: 25498219

Group type: EXPERIMENTAL
Intervention: Sorafenib (800 mg) plus Everolimus (5 mg) once a day until disease progression or unacceptable toxic effects
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sorafenib plus Everolimus
Number of subjects: 38
Study: 25498307

Group type: EXPERIMENTAL
Intervention: Training protocol with visual feedback of respiratory phase and volume for swallowing initiation
Number of subjects: 30
Study: 25499011

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 0
Study: 25499873

Group type: EXPERIMENTAL
Intervention: Bridging anticoagulation (24% of patients, n=665)
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: Bridging anticoagulation
Number of subjects: 2200

Group type: COMPARATOR
Intervention: No bridging anticoagulation (nonbridged patients)
Number of subjects: 2200
Study: 25499989

Group type: EXPERIMENTAL
Intervention: High-definition magnifying endoscopy with multiple-band imaging (HDMEMBI)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard white-light endoscopy (SDWLE)
Number of subjects: 110
Study: 25500165

Group type: EXPERIMENTAL
Intervention: Thoracic spinal cord stimulation (SCS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nontreated controls
Number of subjects: 22
Study: 25500237

Group type: EXPERIMENTAL
Intervention: Intracoronary NIRS imaging with LCBI equal to or above the median (43.0)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Intracoronary NIRS imaging with LCBI below the median
Number of subjects: 203
Study: 25500281

Group type: EXPERIMENTAL
Intervention: ePAL mobile application and usual care
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 110
Study: 25500329

Group type: EXPERIMENTAL
Intervention: Volatile organic compounds (VOCs) analysis in bile samples using selected ion flow tube mass spectrometry.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Predictive model for diagnosis of CCA based on VOC levels.
Number of subjects: 32
Study: 25500680

Group type: EXPERIMENTAL
Intervention: Propofol during induction
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Propofol during maintenance
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Remifentanil during induction
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Remifentanil during maintenance
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Remifentanil during induction (IBW)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Remifentanil during maintenance (IBW)
Number of subjects: 59
Study: 25500831

Group type: EXPERIMENTAL
Intervention: Intravenous tariquidar infusion (2 mg/kg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Intravenous tariquidar infusion (4 mg/kg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Injecting (11)C-dLop after intravenous tariquidar infusion (up to 6 mg/kg)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Oral tariquidar
Number of subjects: 37

Group type: COMPARATOR
Intervention: Oral disulfiram
Number of subjects: 37

Group type: COMPARATOR
Intervention: Injecting (11)C-dLop under baseline conditions without P-gp inhibition
Number of subjects: 37
Study: 25501091

Group type: EXPERIMENTAL
Intervention: High NT-proBNP
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: High cTnT
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: High hsCRP
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Ln NT-proBNP
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 864
Study: 25501110

Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 50
Study: 25501494

Group type: EXPERIMENTAL
Intervention: Intrathecal injection of bupivacaine 1.75 mg and fentanyl 15 μg
Number of subjects: 11
Study: 25501547

Group type: EXPERIMENTAL
Intervention: Cytotoxic T lymphocytes (CTLs) in alcoholic hepatitis
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Natural killer (NK) cells in alcoholic hepatitis
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NK cell degranulation capacity in alcoholic hepatitis
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NKG2D receptor expression on NK cells, CTLs, and NKT cells in alcoholic hepatitis
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: IL-22-producing CTLs and NK cells in alcoholic hepatitis
Number of subjects: 24
Study: 25501820

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication treatment consisting of lansoprazole 30 mg, amoxicillin 1000 mg, and clarithromycin 500 mg orally twice daily for a week.
Number of subjects: 0
Study: 25502635

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT) with in vivo purged progenitor cells
Number of subjects: 124

Group type: COMPARATOR
Intervention: Debulking chemotherapy
Number of subjects: 124

Group type: COMPARATOR
Intervention: Rituximab, cyclophosphamide, vincristine, prednisone (R-COP)
Number of subjects: 124
Study: 25502806

Group type: EXPERIMENTAL
Intervention: GIA diameter measurement
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: GIA volume measurement
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Correlation of GIA diameter and volume
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: GIA location
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Diameter and volume measurements
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Clinical relevance of GIA size
Number of subjects: 66
Study: 25502858

Group type: EXPERIMENTAL
Intervention: Simplified negative-pressure wound therapy
Number of subjects: 37
Study: 25502862

Group type: EXPERIMENTAL
Intervention: SERI Surgical Scaffold
Number of subjects: 139
Study: 25502863

Group type: EXPERIMENTAL
Intervention: Amatuximab (200 mg/m2)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Amatuximab (50 mg/m2)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Amatuximab
Number of subjects: 17
Study: 25503082

Group type: EXPERIMENTAL
Intervention: Tapentadol ER (100-250 mg bid)
Number of subjects: 703

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Tapentadol ER
Number of subjects: 703
Study: 25503302

Group type: EXPERIMENTAL
Intervention: Vandetanib (200 mg) plus sirolimus (2 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Vandetanib plus sirolimus
Number of subjects: 22
Study: 25503419

Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy
Number of subjects: 260

Group type: COMPARATOR
Intervention: No thrombectomy
Number of subjects: 260

Group type: COMPARATOR
Intervention: Small thrombus burden
Number of subjects: 260

Group type: COMPARATOR
Intervention: Prestenting residual thrombus or TIMI flow grade up to 2
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Prestenting TIMI flow grade up to 2
Number of subjects: 260
Study: 25503525

Group type: EXPERIMENTAL
Intervention: Research ethics procedures and committee requirements
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Patient information sheets
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Informed consent requirements
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Details provided to patients
Number of subjects: 23
Study: 25503750

Group type: EXPERIMENTAL
Intervention: FEV1
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 6MWD
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Combined inhaled medication
Number of subjects: 210

Group type: COMPARATOR
Intervention: Physical activity (PAL and steps per day)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Exercise capacity (6MWD)
Number of subjects: 210
Study: 25503901

Group type: EXPERIMENTAL
Intervention: Implant-supported restorative therapy
Number of subjects: 2765
Study: 25504157

Group type: EXPERIMENTAL
Intervention: Desmopressin tablet (once daily)
Number of subjects: 744
Study: 25504765

Group type: EXPERIMENTAL
Intervention: Severe mood dysregulation (SMD)
Number of subjects: 200
Study: 25504813

Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng at doses of 3 g/day
Number of subjects: 35
Study: 25505396

Group type: EXPERIMENTAL
Intervention: Slow Cortical Potential (SCP) neurofeedback protocol
Number of subjects: 58

Group type: COMPARATOR
Intervention: Self-management (SM)
Number of subjects: 58
Study: 25505413

Group type: EXPERIMENTAL
Intervention: 60 min of low to moderate intensity exercise
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 36
Study: 25505693

Group type: EXPERIMENTAL
Intervention: Add-on lithium (600 to 1,800 mg/day)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Add-on placebo
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Add-on lithium
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Lithium in combination with quetiapine XR
Number of subjects: 356
Study: 25505858

Group type: EXPERIMENTAL
Intervention: Compression stockings
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 138
Study: 25506426

Group type: EXPERIMENTAL
Intervention: Nonpostbariatric abdominoplasty
Number of subjects: 64
Study: 25506706

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (children without clinical malaria)
Number of subjects: 61
Study: 25510313

Group type: EXPERIMENTAL
Intervention: Multi-component physical activity intervention (n = 388) during 12 weeks including improvement of physical education, extracurricular activities, activities at home, and health education lectures.
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Multi-component physical activity intervention (n = 388) during 12 weeks.
Number of subjects: 921

Group type: COMPARATOR
Intervention: Usual practice (control group, n = 533).
Number of subjects: 921
Study: 25510385

Group type: EXPERIMENTAL
Intervention: Suspected PE patients (n = 504)
Number of subjects: 1736

Group type: COMPARATOR
Intervention: RPE patients (n = 1232)
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: Suspected PE patients (both PE and RPE)
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: PE patients (n = 504)
Number of subjects: 1736
Study: 25510388

Group type: EXPERIMENTAL
Intervention: MCC-CRM followed by MCC-TT vaccine
Number of subjects: 193

Group type: COMPARATOR
Intervention: Two MCC-CRM vaccines
Number of subjects: 193

Group type: COMPARATOR
Intervention: Two MCC-TT vaccines
Number of subjects: 193

Group type: COMPARATOR
Intervention: MCC-TT followed by MCC-CRM vaccine
Number of subjects: 193
Study: 25510395

Group type: COMPARATOR
Intervention: Women with STEMI
Number of subjects: 11986

Group type: COMPARATOR
Intervention: Women aged <60 with STEMI
Number of subjects: 11986

Group type: COMPARATOR
Intervention: Women aged 60-69 with STEMI
Number of subjects: 11986

Group type: COMPARATOR
Intervention: Women aged 70-79 with STEMI
Number of subjects: 11986

Group type: COMPARATOR
Intervention: Women aged ≥80 with STEMI
Number of subjects: 11986
Study: 25510701

Group type: EXPERIMENTAL
Intervention: DHEA supplementation
Number of subjects: 0
Study: 25510776

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 20
Study: 25510920

Group type: EXPERIMENTAL
Intervention: Silicone oil tamponade
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (fellow unoperated eyes)
Number of subjects: 60
Study: 25511105

Group type: EXPERIMENTAL
Intervention: Serelaxin (30 μg kg(-1) day(-1) via intravenous infusion for 24 hours)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 49
Study: 25511129

Group type: EXPERIMENTAL
Intervention: Hypnotic relaxation suggestion
Number of subjects: 23
Study: 25511306

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) or physical activity monitoring program (home or center based)
Number of subjects: 531
Study: 25511442

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 110
Study: 25511783

Group type: EXPERIMENTAL
Intervention: Patients with stages 3-4 renal dysfunction (GFR <60 mL/min/1.73 m(2))
Number of subjects: 146

Group type: COMPARATOR
Intervention: Patients with stages 1-2 renal dysfunction (normal to mildly impaired)
Number of subjects: 146
Study: 25512030

Group type: EXPERIMENTAL
Intervention: Paclitaxel and trastuzumab neoadjuvant chemotherapy (NC) for 24 weeks, followed by 1 year adjuvant trastuzumab ± hormonal and/or radio-therapy.
Number of subjects: 109

Group type: COMPARATOR
Intervention: Paclitaxel and trastuzumab neoadjuvant chemotherapy (NC) for 24 weeks.
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Trastuzumab-mediated antibody-dependent cell cytotoxicity (ADCC).
Number of subjects: 109